Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Valeant to Cut Addyi Sales Force

By Drug Discovery Trends Editor | April 7, 2016

 (Ryan Remiorz/The Canadian Press via AP, File)In response to six months of disappointing sales of female libido drug, Addyi, Valeant Pharmaceuticals has terminated its sales force — which means that 140 contract workers will be laid off.

The Canadian drugmaker plans to relaunch its sales effort later this year with a team it will assemble internally, according to Bloomberg sources.

In addition to the Addyi contract workers, Valeant is dismissing 140 workers across its dermatology, gastrointestinal and women’s health divisions, in a restructuring effort. Valeant has approximately 22,000 employees.

“While the former team did a great job getting regulatory approval for Addyi, and despite our best efforts with respect to commercialization, sales of Addyi have not met our expectations yet,” Valeant CEO J. Michael Pearson told employees in a memo obtained by Bloomberg.

Addyi won FDA approval in August 2015 amid controversial claims that the drug works minimally better than a placebo, and has substantially harmful side effects.

Read more: Female Libido Drug, Addyi, Shows Modest Results

Sales of Addyi never really took off, partly due to limited insurance coverage for the pill, reported Bloomberg.

Valeant has recently dealt with several issues: Its CEO is leaving after the company reported weak fourth-quarter results. Valeant’s business practices of extensively increasing the costs of acquired drugs have been questioned. And the company is seeking to waive a default and loosen restrictions on its debt.

Read more: Valeant Shares Plunge 50 Percent; Investor Retreat


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE